Hintergrund: Tetrahydrocannabinol (THC) und Cannabidiol (CBD) sind die prominentesten Wirkstoffe aus der weiblichen Hanfpflanze (Cannabis sativa L.). Während sich die Kombination von THC- und CBD-reichen Extrakten dank ihrer analgetischen und antispastischen Wirkungen bei Patienten mit Multipler Sklerose etabliert hat, steht das Anwendungsprofil von CBD noch am Beginn seiner Erforschung. Methoden: Mittels PubMed-Recherchen und Studium der damit gefundenen Literatur wurden Publikationen von klinischen Studien gesucht, bei welchen Aspekte der Wirksamkeit von CBD oder CBD-reichen Extrakten als Monopräparate untersucht wurden. Es konnten 25 Studien identifiziert werden, welche die beschriebenen Kriterien erfüllen. Resultate und Schlussfolgerung: Die meisten ausgewählten Studien sind kontrollierte Pilotstudien mit 20 oder weniger Patienten pro Gruppe oder offene Studien. Evidenz für die Wirksamkeit von CBD gibt es bei Kindern mit therapieresistenter Epilepsie. Die Anzahl der Anfälle konnte bei Kindern mit Dravet-Syndrom in einer Dosierung von 20 mg CBD/kg (zusätzlich zur Standardtherapie) signifikant reduziert werden. Evident ist auch die Wirksamkeit von Dosierungen zwischen 300 und 600 mg bei sozialen Angststörungen. Bezüglich der antipsychotischen Wirkung, der analgetischen Wirkung sowie der Wirkung auf den Schlaf sind die Resultate widersprüchlich.

Keywords:
Cannabidiol, Cannabinoide, Klinische Studie
1.
Devinsky O, Cross JH, Laux L, et al: Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-2020.
2.
Devinsky O, Marsh E, Friedman D, et al: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270-278.
3.
Tzadok M, Uliel-Siboni S, Linder I, et al: CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure 2016;35:41-44.
4.
Hussain SA, Zhou R, Jacobson C, et al: Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 2015;47:138-141.
5.
Consroe P, Laguna J, Allender J, et al: Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991;40:701-708.
6.
Cunha JM, Carlini EA, Pereira AE, et al: Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175-185.
7.
Carlini EA, Cunha JM: Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(suppl):417S-427S.
8.
Gofshteyn JS, Wilfong A, Devinsky O, et al: Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol 2017;32:35-40.
9.
O'Connell BK, Gloss D, Devinsky O: Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav 2017;70:341-348.
10.
Zuardi AW, Rodrigues NP, Silva AL, et al: Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 2017;8:259.
11.
Bergamaschi MM, Queiroz RH, Chagas MH, et al: Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36:1219-1226.
12.
Crippa JA, Derenusson GN, Ferrari TB, et al: Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25:121-130.
13.
Zuardi AW, Cosme RA, Graeff FG, Guimarães FS: Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993;7(suppl):82-88.
14.
Das RK, Kamboj SK, Ramadas M, et al: Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 2013;226:781-792.
15.
GW Pharmaceuticals: GW Pharmaceuticals announces positive proof of concept data in schizophrenia. 15.09.2015. https://www. gwpharm.com/about-us/news/gw-pharmaceuticals-announces-positive-proof-concept-data-schizophrenia.
16.
Leweke FM, Piomelli D, Pahlisch F, et al: Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.
17.
Hallak JE, Machado-de-Sousa JP, Crippa JA, et al: Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010;32:56-61.
18.
Zuardi AW, Crippa JA, Hallak JE, et al: Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009;23:979-983.
19.
Zuardi AW, Hallak JE, Dursun SM, et al: Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006;20:683-686.
20.
Wade DT, Robson P, House H, et al: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. J. Clin Rehabil 2003;17:21-29.
21.
Notcutt W, Price M, Miller R, et al: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1' studies. Anaesthesia 2004;59:440-452.
22.
Morgan CJ, Das RK, Joye A, et al: Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013;38:2433-2436.
23.
Yeshurun M, Shpilberg O, Herscovici C, et al: Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant 2015;21:1770-1775.
24.
Chagas MH, Zuardi AW, Tumas V, et al: Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol 2014;28:1088-1098.
25.
Consroe P, Sandyk R, Snider SR: Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30:277-282.
26.
Tomida I, Azuara-Blanco A, House H, et al: Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 2006;15:349-353.
27.
Osborne AL, Solowij N, Weston-Green K: A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev 2017;72:310- 324.
28.
Pisanti S, Malfitano AM, Ciaglia E, et al: Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 2017;175:133-150.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.